Translational Development Acquisition (TDAC) Equity Average (2024 - 2026)
Translational Development Acquisition's Equity Average history spans 3 years, with the latest figure at -$6.7 million for Q1 2026.
- On a quarterly basis, Equity Average fell 15.79% to -$6.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.7 million, a 15.79% decrease, with the full-year FY2025 number at -$6.1 million, down 98.84% from a year prior.
- Equity Average came in at -$6.7 million for Q1 2026, down from -$6.5 million in the prior quarter.
- The five-year high for Equity Average was -$508500.5 in Q2 2024, with the low at -$6.7 million in Q1 2026.
- Historically, Equity Average has averaged -$4.4 million across 3 years, with a median of -$5.9 million in 2025.
- Biggest five-year swings in Equity Average: tumbled 1090.86% in 2025 and later dropped 15.79% in 2026.
- Year by year, Equity Average stood at -$3.1 million in 2024, then plummeted by 109.49% to -$6.5 million in 2025, then fell by 3.43% to -$6.7 million in 2026.
- Business Quant data shows Equity Average for TDAC at -$6.7 million in Q1 2026, -$6.5 million in Q4 2025, and -$6.3 million in Q3 2025.